Site Announcement
For the latest results and update on CytoDyn’s Phase 2 CRC trial and more, here’s a link to our April 30, 2026 investor update webinar
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 04/09/18 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
   |
41 |
| 03/30/18 | UPLOAD | SEC-generated letter |
|
2 | |
| 03/26/18 | SC TO-I/A | Issuer tender offer statement |
|
4 | |
| 03/26/18 | 8-K | Current report filing |
|
3 | |
| 03/26/18 | 8-K | Current report filing |
|
22 | |
| 03/23/18 | EFFECT | Notice of Effectiveness |
|
1 | |
| 03/23/18 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans |
|
31 | |
| 03/23/18 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
29 | |
| 03/22/18 | S-3/A | Registration statement for specified transactions by certain issuers |
|
38 | |
| 03/21/18 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 |
